img

Global Glucagon Injectable Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Glucagon Injectable Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The global Glucagon Injectable market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Glucagon Injectable is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Glucagon Injectable is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Glucagon Injectable is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Glucagon Injectable include Fresenius SE & Co. KGaA, Xeris Pharmaceuticals Inc, Novo Nordisk A/S, ILS.Inc, Amphastar Pharmaceuticals Inc., Lilly USA, LLC, Zealand Pharma A/S. and Avalon Pharma Pvt. Ltd., etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Glucagon Injectable, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Glucagon Injectable by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Glucagon Injectable market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Glucagon Injectable market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Fresenius SE & Co. KGaA
Xeris Pharmaceuticals Inc
Novo Nordisk A/S
ILS.Inc
Amphastar Pharmaceuticals Inc.
Lilly USA, LLC
Zealand Pharma A/S.
Avalon Pharma Pvt. Ltd.
By Type
Children
Adults
By Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Sales by Region
North America
United States
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Glucagon Injectable in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Glucagon Injectable manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Glucagon Injectable sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Glucagon Injectable Definition
1.2 Market by Type
1.2.1 Global Glucagon Injectable Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Children
1.2.3 Adults
1.3 Market Segment by Application
1.3.1 Global Glucagon Injectable Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Glucagon Injectable Sales
2.1 Global Glucagon Injectable Revenue Estimates and Forecasts 2018-2034
2.2 Global Glucagon Injectable Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Glucagon Injectable Revenue by Region
2.3.1 Global Glucagon Injectable Revenue by Region (2018-2024)
2.3.2 Global Glucagon Injectable Revenue by Region (2024-2034)
2.4 Global Glucagon Injectable Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Glucagon Injectable Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Glucagon Injectable Sales Quantity by Region
2.6.1 Global Glucagon Injectable Sales Quantity by Region (2018-2024)
2.6.2 Global Glucagon Injectable Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Glucagon Injectable Sales Quantity by Manufacturers
3.1.1 Global Glucagon Injectable Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Glucagon Injectable Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Glucagon Injectable Sales in 2022
3.2 Global Glucagon Injectable Revenue by Manufacturers
3.2.1 Global Glucagon Injectable Revenue by Manufacturers (2018-2024)
3.2.2 Global Glucagon Injectable Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Glucagon Injectable Revenue in 2022
3.3 Global Glucagon Injectable Sales Price by Manufacturers
3.4 Global Key Players of Glucagon Injectable, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Glucagon Injectable Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Glucagon Injectable, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Glucagon Injectable, Product Offered and Application
3.8 Global Key Manufacturers of Glucagon Injectable, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Glucagon Injectable Sales Quantity by Type
4.1.1 Global Glucagon Injectable Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Glucagon Injectable Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Glucagon Injectable Sales Quantity Market Share by Type (2018-2034)
4.2 Global Glucagon Injectable Revenue by Type
4.2.1 Global Glucagon Injectable Historical Revenue by Type (2018-2024)
4.2.2 Global Glucagon Injectable Forecasted Revenue by Type (2024-2034)
4.2.3 Global Glucagon Injectable Revenue Market Share by Type (2018-2034)
4.3 Global Glucagon Injectable Price by Type
4.3.1 Global Glucagon Injectable Price by Type (2018-2024)
4.3.2 Global Glucagon Injectable Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Glucagon Injectable Sales Quantity by Application
5.1.1 Global Glucagon Injectable Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Glucagon Injectable Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Glucagon Injectable Sales Quantity Market Share by Application (2018-2034)
5.2 Global Glucagon Injectable Revenue by Application
5.2.1 Global Glucagon Injectable Historical Revenue by Application (2018-2024)
5.2.2 Global Glucagon Injectable Forecasted Revenue by Application (2024-2034)
5.2.3 Global Glucagon Injectable Revenue Market Share by Application (2018-2034)
5.3 Global Glucagon Injectable Price by Application
5.3.1 Global Glucagon Injectable Price by Application (2018-2024)
5.3.2 Global Glucagon Injectable Price Forecast by Application (2024-2034)
6 North America
6.1 North America Glucagon Injectable Sales by Company
6.1.1 North America Glucagon Injectable Revenue by Company (2018-2024)
6.1.2 North America Glucagon Injectable Sales Quantity by Company (2018-2024)
6.2 North America Glucagon Injectable Market Size by Type
6.2.1 North America Glucagon Injectable Sales Quantity by Type (2018-2034)
6.2.2 North America Glucagon Injectable Revenue by Type (2018-2034)
6.3 North America Glucagon Injectable Market Size by Application
6.3.1 North America Glucagon Injectable Sales Quantity by Application (2018-2034)
6.3.2 North America Glucagon Injectable Revenue by Application (2018-2034)
6.4 North America Glucagon Injectable Market Size by Country
6.4.1 North America Glucagon Injectable Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Glucagon Injectable Revenue by Country (2018-2034)
6.4.3 North America Glucagon Injectable Sales Quantity by Country (2018-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Glucagon Injectable Sales by Company
7.1.1 Europe Glucagon Injectable Sales Quantity by Company (2018-2024)
7.1.2 Europe Glucagon Injectable Revenue by Company (2018-2024)
7.2 Europe Glucagon Injectable Market Size by Type
7.2.1 Europe Glucagon Injectable Sales Quantity by Type (2018-2034)
7.2.2 Europe Glucagon Injectable Revenue by Type (2018-2034)
7.3 Europe Glucagon Injectable Market Size by Application
7.3.1 Europe Glucagon Injectable Sales Quantity by Application (2018-2034)
7.3.2 Europe Glucagon Injectable Revenue by Application (2018-2034)
7.4 Europe Glucagon Injectable Market Size by Country
7.4.1 Europe Glucagon Injectable Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Glucagon Injectable Revenue by Country (2018-2034)
7.4.3 Europe Glucagon Injectable Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Glucagon Injectable Sales by Company
8.1.1 China Glucagon Injectable Sales Quantity by Company (2018-2024)
8.1.2 China Glucagon Injectable Revenue by Company (2018-2024)
8.2 China Glucagon Injectable Market Size by Type
8.2.1 China Glucagon Injectable Sales Quantity by Type (2018-2034)
8.2.2 China Glucagon Injectable Revenue by Type (2018-2034)
8.3 China Glucagon Injectable Market Size by Application
8.3.1 China Glucagon Injectable Sales Quantity by Application (2018-2034)
8.3.2 China Glucagon Injectable Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Glucagon Injectable Sales by Company
9.1.1 APAC Glucagon Injectable Sales Quantity by Company (2018-2024)
9.1.2 APAC Glucagon Injectable Revenue by Company (2018-2024)
9.2 APAC Glucagon Injectable Market Size by Type
9.2.1 APAC Glucagon Injectable Sales Quantity by Type (2018-2034)
9.2.2 APAC Glucagon Injectable Revenue by Type (2018-2034)
9.3 APAC Glucagon Injectable Market Size by Application
9.3.1 APAC Glucagon Injectable Sales Quantity by Application (2018-2034)
9.3.2 APAC Glucagon Injectable Revenue by Application (2018-2034)
9.4 APAC Glucagon Injectable Market Size by Region
9.4.1 APAC Glucagon Injectable Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Glucagon Injectable Revenue by Region (2018-2034)
9.4.3 APAC Glucagon Injectable Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Glucagon Injectable Sales by Company
10.1.1 Middle East, Africa and Latin America Glucagon Injectable Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Glucagon Injectable Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Glucagon Injectable Market Size by Type
10.2.1 Middle East, Africa and Latin America Glucagon Injectable Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Glucagon Injectable Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Glucagon Injectable Market Size by Application
10.3.1 Middle East, Africa and Latin America Glucagon Injectable Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Glucagon Injectable Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Glucagon Injectable Market Size by Country
10.4.1 Middle East, Africa and Latin America Glucagon Injectable Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Glucagon Injectable Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Glucagon Injectable Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Fresenius SE & Co. KGaA
11.1.1 Fresenius SE & Co. KGaA Company Information
11.1.2 Fresenius SE & Co. KGaA Overview
11.1.3 Fresenius SE & Co. KGaA Glucagon Injectable Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Fresenius SE & Co. KGaA Glucagon Injectable Products and Services
11.1.5 Fresenius SE & Co. KGaA Glucagon Injectable SWOT Analysis
11.1.6 Fresenius SE & Co. KGaA Recent Developments
11.2 Xeris Pharmaceuticals Inc
11.2.1 Xeris Pharmaceuticals Inc Company Information
11.2.2 Xeris Pharmaceuticals Inc Overview
11.2.3 Xeris Pharmaceuticals Inc Glucagon Injectable Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Xeris Pharmaceuticals Inc Glucagon Injectable Products and Services
11.2.5 Xeris Pharmaceuticals Inc Glucagon Injectable SWOT Analysis
11.2.6 Xeris Pharmaceuticals Inc Recent Developments
11.3 Novo Nordisk A/S
11.3.1 Novo Nordisk A/S Company Information
11.3.2 Novo Nordisk A/S Overview
11.3.3 Novo Nordisk A/S Glucagon Injectable Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Novo Nordisk A/S Glucagon Injectable Products and Services
11.3.5 Novo Nordisk A/S Glucagon Injectable SWOT Analysis
11.3.6 Novo Nordisk A/S Recent Developments
11.4 ILS.Inc
11.4.1 ILS.Inc Company Information
11.4.2 ILS.Inc Overview
11.4.3 ILS.Inc Glucagon Injectable Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 ILS.Inc Glucagon Injectable Products and Services
11.4.5 ILS.Inc Glucagon Injectable SWOT Analysis
11.4.6 ILS.Inc Recent Developments
11.5 Amphastar Pharmaceuticals Inc.
11.5.1 Amphastar Pharmaceuticals Inc. Company Information
11.5.2 Amphastar Pharmaceuticals Inc. Overview
11.5.3 Amphastar Pharmaceuticals Inc. Glucagon Injectable Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Amphastar Pharmaceuticals Inc. Glucagon Injectable Products and Services
11.5.5 Amphastar Pharmaceuticals Inc. Glucagon Injectable SWOT Analysis
11.5.6 Amphastar Pharmaceuticals Inc. Recent Developments
11.6 Lilly USA, LLC
11.6.1 Lilly USA, LLC Company Information
11.6.2 Lilly USA, LLC Overview
11.6.3 Lilly USA, LLC Glucagon Injectable Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Lilly USA, LLC Glucagon Injectable Products and Services
11.6.5 Lilly USA, LLC Glucagon Injectable SWOT Analysis
11.6.6 Lilly USA, LLC Recent Developments
11.7 Zealand Pharma A/S.
11.7.1 Zealand Pharma A/S. Company Information
11.7.2 Zealand Pharma A/S. Overview
11.7.3 Zealand Pharma A/S. Glucagon Injectable Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Zealand Pharma A/S. Glucagon Injectable Products and Services
11.7.5 Zealand Pharma A/S. Glucagon Injectable SWOT Analysis
11.7.6 Zealand Pharma A/S. Recent Developments
11.8 Avalon Pharma Pvt. Ltd.
11.8.1 Avalon Pharma Pvt. Ltd. Company Information
11.8.2 Avalon Pharma Pvt. Ltd. Overview
11.8.3 Avalon Pharma Pvt. Ltd. Glucagon Injectable Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Avalon Pharma Pvt. Ltd. Glucagon Injectable Products and Services
11.8.5 Avalon Pharma Pvt. Ltd. Glucagon Injectable SWOT Analysis
11.8.6 Avalon Pharma Pvt. Ltd. Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Glucagon Injectable Value Chain Analysis
12.2 Glucagon Injectable Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Glucagon Injectable Production Mode & Process
12.4 Glucagon Injectable Sales and Marketing
12.4.1 Glucagon Injectable Sales Channels
12.4.2 Glucagon Injectable Distributors
12.5 Glucagon Injectable Customers
13 Market Dynamics
13.1 Glucagon Injectable Industry Trends
13.2 Glucagon Injectable Market Drivers
13.3 Glucagon Injectable Market Challenges
13.4 Glucagon Injectable Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Glucagon Injectable Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Children
Table 3. Major Manufacturers of Adults
Table 4. Global Glucagon Injectable Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Glucagon Injectable Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Glucagon Injectable Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Glucagon Injectable Revenue Market Share by Region (2018-2024)
Table 8. Global Glucagon Injectable Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Glucagon Injectable Revenue Market Share by Region (2024-2034)
Table 10. Global Glucagon Injectable Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 11. Global Glucagon Injectable Sales by Region (2018-2024) & (K Units)
Table 12. Global Glucagon Injectable Sales Market Share by Region (2018-2024)
Table 13. Global Glucagon Injectable Sales by Region (2024-2034) & (K Units)
Table 14. Global Glucagon Injectable Sales Market Share by Region (2024-2034)
Table 15. Global Glucagon Injectable Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 16. Global Glucagon Injectable Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Glucagon Injectable Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Glucagon Injectable Revenue Share by Manufacturers (2018-2024)
Table 19. Global Glucagon Injectable Price by Manufacturers 2018-2024 (USD/Unit)
Table 20. Global Key Players of Glucagon Injectable, Industry Ranking, 2021 VS 2022
Table 21. Global Glucagon Injectable Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Glucagon Injectable by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glucagon Injectable as of 2022)
Table 23. Global Key Manufacturers of Glucagon Injectable, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Glucagon Injectable, Product Offered and Application
Table 25. Global Key Manufacturers of Glucagon Injectable, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Glucagon Injectable Sales Quantity by Type (2018-2024) & (K Units)
Table 28. Global Glucagon Injectable Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Glucagon Injectable Sales Quantity Share by Type (2018-2024)
Table 30. Global Glucagon Injectable Sales Quantity Share by Type (2024-2034)
Table 31. Global Glucagon Injectable Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Glucagon Injectable Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Glucagon Injectable Revenue Share by Type (2018-2024)
Table 34. Global Glucagon Injectable Revenue Share by Type (2024-2034)
Table 35. Glucagon Injectable Price by Type (2018-2024) & (USD/Unit)
Table 36. Global Glucagon Injectable Price Forecast by Type (2024-2034) & (USD/Unit)
Table 37. Global Glucagon Injectable Sales Quantity by Application (2018-2024) & (K Units)
Table 38. Global Glucagon Injectable Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Glucagon Injectable Sales Quantity Share by Application (2018-2024)
Table 40. Global Glucagon Injectable Sales Quantity Share by Application (2024-2034)
Table 41. Global Glucagon Injectable Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Glucagon Injectable Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Glucagon Injectable Revenue Share by Application (2018-2024)
Table 44. Global Glucagon Injectable Revenue Share by Application (2024-2034)
Table 45. Glucagon Injectable Price by Application (2018-2024) & (USD/Unit)
Table 46. Global Glucagon Injectable Price Forecast by Application (2024-2034) & (USD/Unit)
Table 47. North America Glucagon Injectable Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Glucagon Injectable Sales Quantity by Company (2018-2024) & (K Units)
Table 49. North America Glucagon Injectable Sales Quantity by Type (2018-2024) & (K Units)
Table 50. North America Glucagon Injectable Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Glucagon Injectable Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Glucagon Injectable Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Glucagon Injectable Sales Quantity by Application (2018-2024) & (K Units)
Table 54. North America Glucagon Injectable Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Glucagon Injectable Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Glucagon Injectable Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Glucagon Injectable Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Glucagon Injectable Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Glucagon Injectable Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Glucagon Injectable Sales Quantity by Country (2018-2024) & (K Units)
Table 61. North America Glucagon Injectable Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Glucagon Injectable Sales Quantity by Company (2018-2024) & (K Units)
Table 63. Europe Glucagon Injectable Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Glucagon Injectable Sales Quantity by Type (2018-2024) & (K Units)
Table 65. Europe Glucagon Injectable Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Glucagon Injectable Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Glucagon Injectable Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Glucagon Injectable Sales Quantity by Application (2018-2024) & (K Units)
Table 69. Europe Glucagon Injectable Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Glucagon Injectable Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Glucagon Injectable Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Glucagon Injectable Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Glucagon Injectable Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Glucagon Injectable Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Glucagon Injectable Sales Quantity by Country (2018-2024) & (K Units)
Table 76. Europe Glucagon Injectable Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Glucagon Injectable Sales Quantity by Company (2018-2024) & (K Units)
Table 78. China Glucagon Injectable Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Glucagon Injectable Sales Quantity by Type (2018-2024) & (K Units)
Table 80. China Glucagon Injectable Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Glucagon Injectable Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Glucagon Injectable Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Glucagon Injectable Sales Quantity by Application (2018-2024) & (K Units)
Table 84. China Glucagon Injectable Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Glucagon Injectable Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Glucagon Injectable Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Glucagon Injectable Sales Quantity by Company (2018-2024) & (K Units)
Table 88. APAC Glucagon Injectable Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Glucagon Injectable Sales Quantity by Type (2018-2024) & (K Units)
Table 90. APAC Glucagon Injectable Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Glucagon Injectable Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Glucagon Injectable Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Glucagon Injectable Sales Quantity by Application (2018-2024) & (K Units)
Table 94. APAC Glucagon Injectable Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Glucagon Injectable Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Glucagon Injectable Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Glucagon Injectable Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Glucagon Injectable Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Glucagon Injectable Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Glucagon Injectable Sales Quantity by Region (2018-2024) & (K Units)
Table 101. APAC Glucagon Injectable Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity by Company (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Glucagon Injectable Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity by Type (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Glucagon Injectable Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Glucagon Injectable Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity by Application (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Glucagon Injectable Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Glucagon Injectable Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Glucagon Injectable Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Glucagon Injectable Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Glucagon Injectable Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity by Country (2018-2024) & (K Units)
Table 116. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Fresenius SE & Co. KGaA Company Information
Table 118. Fresenius SE & Co. KGaA Description and Overview
Table 119. Fresenius SE & Co. KGaA Glucagon Injectable Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 120. Fresenius SE & Co. KGaA Glucagon Injectable Product and Services
Table 121. Fresenius SE & Co. KGaA Glucagon Injectable SWOT Analysis
Table 122. Fresenius SE & Co. KGaA Recent Developments
Table 123. Xeris Pharmaceuticals Inc Company Information
Table 124. Xeris Pharmaceuticals Inc Description and Overview
Table 125. Xeris Pharmaceuticals Inc Glucagon Injectable Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 126. Xeris Pharmaceuticals Inc Glucagon Injectable Product and Services
Table 127. Xeris Pharmaceuticals Inc Glucagon Injectable SWOT Analysis
Table 128. Xeris Pharmaceuticals Inc Recent Developments
Table 129. Novo Nordisk A/S Company Information
Table 130. Novo Nordisk A/S Description and Overview
Table 131. Novo Nordisk A/S Glucagon Injectable Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 132. Novo Nordisk A/S Glucagon Injectable Product and Services
Table 133. Novo Nordisk A/S Glucagon Injectable SWOT Analysis
Table 134. Novo Nordisk A/S Recent Developments
Table 135. ILS.Inc Company Information
Table 136. ILS.Inc Description and Overview
Table 137. ILS.Inc Glucagon Injectable Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 138. ILS.Inc Glucagon Injectable Product and Services
Table 139. ILS.Inc Glucagon Injectable SWOT Analysis
Table 140. ILS.Inc Recent Developments
Table 141. Amphastar Pharmaceuticals Inc. Company Information
Table 142. Amphastar Pharmaceuticals Inc. Description and Overview
Table 143. Amphastar Pharmaceuticals Inc. Glucagon Injectable Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 144. Amphastar Pharmaceuticals Inc. Glucagon Injectable Product and Services
Table 145. Amphastar Pharmaceuticals Inc. Glucagon Injectable SWOT Analysis
Table 146. Amphastar Pharmaceuticals Inc. Recent Developments
Table 147. Lilly USA, LLC Company Information
Table 148. Lilly USA, LLC Description and Overview
Table 149. Lilly USA, LLC Glucagon Injectable Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 150. Lilly USA, LLC Glucagon Injectable Product and Services
Table 151. Lilly USA, LLC Glucagon Injectable SWOT Analysis
Table 152. Lilly USA, LLC Recent Developments
Table 153. Zealand Pharma A/S. Company Information
Table 154. Zealand Pharma A/S. Description and Overview
Table 155. Zealand Pharma A/S. Glucagon Injectable Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 156. Zealand Pharma A/S. Glucagon Injectable Product and Services
Table 157. Zealand Pharma A/S. Glucagon Injectable SWOT Analysis
Table 158. Zealand Pharma A/S. Recent Developments
Table 159. Avalon Pharma Pvt. Ltd. Company Information
Table 160. Avalon Pharma Pvt. Ltd. Description and Overview
Table 161. Avalon Pharma Pvt. Ltd. Glucagon Injectable Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 162. Avalon Pharma Pvt. Ltd. Glucagon Injectable Product and Services
Table 163. Avalon Pharma Pvt. Ltd. Glucagon Injectable SWOT Analysis
Table 164. Avalon Pharma Pvt. Ltd. Recent Developments
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Glucagon Injectable Distributors List
Table 168. Glucagon Injectable Customers List
Table 169. Glucagon Injectable Market Trends
Table 170. Glucagon Injectable Market Drivers
Table 171. Glucagon Injectable Market Challenges
Table 172. Glucagon Injectable Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Glucagon Injectable Product Picture
Figure 2. Global Glucagon Injectable Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Glucagon Injectable Market Share by Type in 2022 & 2034
Figure 4. Children Product Picture
Figure 5. Adults Product Picture
Figure 6. Global Glucagon Injectable Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Glucagon Injectable Market Share by Application in 2022 & 2034
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Online Pharmacies
Figure 11. Others
Figure 12. Glucagon Injectable Report Years Considered
Figure 13. Global Glucagon Injectable Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Glucagon Injectable Revenue 2018-2034 (US$ Million)
Figure 15. Global Glucagon Injectable Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 16. Global Glucagon Injectable Sales Quantity 2018-2034 (K Units)
Figure 17. Global Glucagon Injectable Sales Quantity Market Share by Region (2018-2024)
Figure 18. Global Glucagon Injectable Sales Quantity Market Share by Region (2024-2034)
Figure 19. North America Glucagon Injectable Sales Quantity YoY (2018-2034) & (K Units)
Figure 20. North America Glucagon Injectable Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Glucagon Injectable Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. Europe Glucagon Injectable Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Glucagon Injectable Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. China Glucagon Injectable Revenue YoY (2018-2034) & (US$ Million)
Figure 25. APAC Glucagon Injectable Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. APAC Glucagon Injectable Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. Middle East, Africa and Latin America Glucagon Injectable Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Top 10 and Top 5 Players Market Share by Glucagon Injectable Sales Quantity in 2022
Figure 30. The Top 10 and Top 5 Players Market Share by Glucagon Injectable Revenue in 2022
Figure 31. Glucagon Injectable Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Glucagon Injectable Sales Quantity Market Share by Type (2018-2034)
Figure 33. Global Glucagon Injectable Revenue Market Share by Type (2018-2034)
Figure 34. Global Glucagon Injectable Sales Quantity Market Share by Application (2018-2034)
Figure 35. Global Glucagon Injectable Revenue Market Share by Application (2018-2034)
Figure 36. North America Glucagon Injectable Revenue Market Share by Company in 2022
Figure 37. North America Glucagon Injectable Sales Quantity Market Share by Company in 2022
Figure 38. North America Glucagon Injectable Sales Quantity Market Share by Type (2018-2034)
Figure 39. North America Glucagon Injectable Revenue Market Share by Type (2018-2034)
Figure 40. North America Glucagon Injectable Sales Quantity Market Share by Application (2018-2034)
Figure 41. North America Glucagon Injectable Revenue Market Share by Application (2018-2034)
Figure 42. North America Glucagon Injectable Revenue Share by Country (2018-2034)
Figure 43. North America Glucagon Injectable Sales Quantity Share by Country (2018-2034)
Figure 44. United States Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 45. Canada Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 46. Europe Glucagon Injectable Sales Quantity Market Share by Company in 2022
Figure 47. Europe Glucagon Injectable Revenue Market Share by Company in 2022
Figure 48. Europe Glucagon Injectable Sales Quantity Market Share by Type (2018-2034)
Figure 49. Europe Glucagon Injectable Revenue Market Share by Type (2018-2034)
Figure 50. Europe Glucagon Injectable Sales Quantity Market Share by Application (2018-2034)
Figure 51. Europe Glucagon Injectable Revenue Market Share by Application (2018-2034)
Figure 52. Europe Glucagon Injectable Revenue Share by Country (2018-2034)
Figure 53. Europe Glucagon Injectable Sales Quantity Share by Country (2018-2034)
Figure 54. Germany Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 55. France Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 56. U.K. Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 57. Italy Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 58. Russia Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 59. China Glucagon Injectable Sales Quantity Market Share by Company in 2022
Figure 60. China Glucagon Injectable Revenue Market Share by Company in 2022
Figure 61. China Glucagon Injectable Sales Quantity Market Share by Type (2018-2034)
Figure 62. China Glucagon Injectable Revenue Market Share by Type (2018-2034)
Figure 63. China Glucagon Injectable Sales Quantity Market Share by Application (2018-2034)
Figure 64. China Glucagon Injectable Revenue Market Share by Application (2018-2034)
Figure 65. APAC Glucagon Injectable Sales Quantity Market Share by Company in 2022
Figure 66. APAC Glucagon Injectable Revenue Market Share by Company in 2022
Figure 67. APAC Glucagon Injectable Sales Quantity Market Share by Type (2018-2034)
Figure 68. APAC Glucagon Injectable Revenue Market Share by Type (2018-2034)
Figure 69. APAC Glucagon Injectable Sales Quantity Market Share by Application (2018-2034)
Figure 70. APAC Glucagon Injectable Revenue Market Share by Application (2018-2034)
Figure 71. APAC Glucagon Injectable Revenue Share by Region (2018-2034)
Figure 72. APAC Glucagon Injectable Sales Quantity Share by Region (2018-2034)
Figure 73. Japan Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 74. South Korea Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 75. China Taiwan Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 76. Southeast Asia Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 77. India Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 78. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Glucagon Injectable Revenue Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Glucagon Injectable Revenue Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Glucagon Injectable Revenue Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Glucagon Injectable Sales Quantity Share by Country (2018-2034)
Figure 85. Middle East, Africa and Latin America Glucagon Injectable Revenue Share by Country (2018-2034)
Figure 86. Brazil Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 87. Mexico Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 88. Turkey Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 89. Israel Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 90. GCC Countries Glucagon Injectable Revenue (2018-2034) & (US$ Million)
Figure 91. Glucagon Injectable Value Chain
Figure 92. Glucagon Injectable Production Process
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Distributors Profiles
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed